Abstract: Background. AlloDerm® acellular dermal matrix ([ADM], Lifecell Corp, Branchburg, NJ) is gaining increasing popularity in virtually every surgical subspecialty for use in the closure of soft tissue defects, structural support, or tissue augmentation. There is limited experience in lower extremity fascial reconstruction secondary to trauma, as this can be a challenging problem for the plastic surgeon. The purpose of this case report is to demonstrate the reliability of acellular dermal matrix grafts in lower extremity fascial reconstructions. Methods.

Abstract: Chronic and acute wounds with long tunneling or undermining are always a challenge to wound care providers. One of the most frequently employed treatments for closing tunneled or undermined wounds is negative pressure wound therapy (NPWT). The benefits of this treatment system are widely discussed in the professional literature, and will not be covered here. Even though NPWT allows for faster wound healing initially, in some cases, progress to wound closure is limited and healing stops after reaching a maximum potential, which may occur after just a few weeks.

Healthpoint Initiates Study to Evaluate Cell Based Therapy’s Effectiveness

     In September 2008, Tom Dugan became the President for Smith & Nephew’s North American Advanced Wound Management Division (St. Petersburg, Fla). Tom joined the company and wound care market with an impressive 28 years of medical device experience. He began his career working for Johnson & Johnson’s Critikon division. Following several sales, marketing, and corporate management positions, Tom became Senior VP for SonoSite (Bothell, Wa), the worldwide leader in hand-carried ultrasound.